Carvacrol Protects Against Tumor Necrosis Factor-Mediated Inflammation In Vascular Smooth Muscle Cell Through Nf-Kappa B Pathway

Hongtao Zhou,Xuefang Yu,Guiming Zhou
2017-01-01
Abstract:Atherosclerosis is a chronic inflammatory disease associated with increased expression of adhesion molecules in vascular smooth muscle cells (VSMCs). Carvacrol, a cyclic monoterpene, exerts protective activities in a variety of pathological states including tumor growth, inflammation, and oxidative stress. Recent studies have indicated that carvacrol has a reverse effect on vascular neointimal formation. However, its detailed mechanisms require further study to provide more scientific evidence for the clinical treatment of atherosclerosis. In the present study, we investigate the effect of carvacrol on the expression of VCAM-1 and ICAM-1 induced by TNF-alpha in cultured VSMCs. Pretreatment of VSMCs for 2 h with carvacrol (0.1-1 mu M) dose-dependently inhibited TNF-alpha-induced protein and mRNA expression of VCAM-1 and ICAM-1. Carvacrol also suppressed TNF-alpha-induced production of intracellular reactive oxygen species (ROS) and activation of p38, ERK and JNK. Furthermore, carvacrol inhibited NK-kappa B activation induced by TNF-alpha. Carvacrol inhibited TNF-alpha-induced I kappa B kinase activation, subsequent degradation of I kappa B alpha and nuclear translocation of p65 NF-kappa B protein level. This study suggests that carvacrol downregulates the TNF-alpha-mediated induction of VCAM-1 and ICAM-1 in VSMCS by inhibiting the NF-kappa B, MAPK signaling pathways and intracellular ROS production. Thus, carvacrol may have beneficial effects to suppress inflammation within the atherosclerotic lesion.
What problem does this paper attempt to address?